- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| EXTRAWELL PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 30.06. | EXTRAWELL PHAR (00858): ANNUAL RESULTS FOR THE YEAR ENDED 31 MARCH 2026 | 1 | HKEx | ||
| 23.06. | EXTRAWELL PHAR (00858): PROFIT WARNING | - | HKEx | ||
| 16.06. | EXTRAWELL PHAR (00858): DATE OF BOARD MEETING | 2 | HKEx | ||
| 29.05. | EXTRAWELL PHAR (00858): (1) FURTHER EXTENSION OF LONG STOP DATE IN RESPECT OF PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS (2) ... | - | HKEx | ||
| 14.04. | EXTRAWELL PHAR (00858): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 27.03. | EXTRAWELL PHAR (00858): MEMORANDUM OF UNDERSTANDING IN RELATION TO THE POSSIBLE SALE OF THE CONVERTIBLE BONDS | - | HKEx | ||
| 17.03. | EXTRAWELL PHAR (00858): COMPLETION OF DISCLOSEABLE TRANSACTION AND CONNECTED TRANSACTION AT SUBSIDIARY LEVEL IN RELATION TO A SHARE BUY-BACK TRANSACTION ... | - | HKEx | ||
| 27.02. | EXTRAWELL PHAR (00858): (1) EXTENSION OF LONG STOP DATE IN RESPECT OF PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS (2) DELAY IN ... | - | HKEx |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 47,100 | +1,53 % | Guggenheim cuts Ionis stock price target on Tryngolza sales outlook | ||
| CSPC PHARMA | 0,925 | -1,98 % | CSPC PHARMA New Drug Application for Disitamab Vedotin for Injection Accepted by China's NMPA | ||
| SELLAS LIFE SCIENCES | 10,900 | -0,46 % | Sellas Life (SLS) Climbs 12% Ahead of 'Potentially Company-Defining' Clinical Trial Result | ||
| MADRIGAL PHARMACEUTICALS | 465,90 | -0,72 % | Citizens raises Madrigal Pharmaceuticals price target on lower tax assumptions | ||
| ACADIA PHARMACEUTICALS | 23,160 | +5,42 % | Stifel erhöht Kursziel für Acadia Pharmaceuticals wegen Medikamentenpotenzial | ||
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | XFRA CN2: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCATALYST PHARM.INC.DL-001... ► Artikel lesen | |
| OPUS GENETICS | 2,700 | +1,50 % | Opus Genetics, Inc.: Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results | RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the "Company", "Opus Genetics" or "Opus"), a clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| SAVARA | 4,789 | -0,52 % | Savara Inc.: Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | -- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (BLA) and MAA in Autoimmune PAP by the U.S. Food and Drug Administration (FDA) and the European Medicines... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - June 29, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 3,480 | +4,19 % | Galectin Therapeutics Inc.: Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension | Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectinCompany intends to file the Phase 3 protocol in Q3 2026... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 2,010 | -5,63 % | Biodexa Pharmaceuticals Plc - F-1, Registration statement for certain foreign private issuers | ||
| NEURIZON THERAPEUTICS | 0,030 | 0,00 % | Neurizon Therapeutics Limited: HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027 | 250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform... ► Artikel lesen | |
| CIPHER PHARMACEUTICALS | 9,800 | 0,00 % | Cipher Pharmaceuticals and the pan-Canadian Pharmaceutical Alliance (pCPA) Sign Letter of Intent for Public Drug Plan Coverage of Epuris | ||
| ACURA PHARMACEUTICALS | - | - | ACURA PHARMACEUTICALS, INC - 8-K, Current Report | ||
| VASO | - | - | Vaso Corporation Announces Financial Results for First Quarter of 2026 | PLAINVIEW, N.Y., May 15, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional... ► Artikel lesen |
EXTRAWELL PHARMACEUTICAL HOLDINGS LTD gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXTRAWELL PHARMACEUTICAL HOLDINGS LTD finden Sie auf Wallstreet Online.